Specialty drugs

Global Hemophilia Pipeline Insights 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Pharmaceutical, Health, Clinical Trials, Haemophilia, Specialty drugs, Biotechnology, Swedish Orphan Biovitrum

The "Global Hemophilia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hemophilia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The latest research provides comprehensive insights into Hemophilia pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • It also provides insights into Hemophilia epidemiology and late-stage pipeline.
  • This research covers the following - Hemophilia treatment options, Hemophilia late-stage clinical trials pipeline, Hemophilia prevalence by countries, Hemophilia market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Biotechnology, Articles, Specialty drugs, Kura, Biopharmaceutical, Precision medicine, Oncology

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference.

Key Points: 
  • SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference.
  • Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel titled Bullseye - Targeted Oncology Part 2 at 10:20 a.m.
  • Kura Oncologyis a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • For additional information about Kura, please visit the Companys website at www.kuraoncology.com .

Aetna, CVS Health to enter the Affordable Care Act (ACA) individual insurance exchange marketplace in North Carolina for January 1, 2022

Retrieved on: 
Wednesday, August 4, 2021
CVS Health, Woonsocket, Rhode Island, Health care, Specialty drugs, Health, Companies, MinuteClinic, CVS Pharmacy, Health maintenance organizations, Aetna, CVS

WOONSOCKET, R.I., Aug. 4, 2021 /PRNewswire/ -- Aetna and CVS Health (NYSE: CVS) will enter the individual insurance exchange marketplace in select counties in North Carolina with their first Aetna CVS Health hybrid-branded insurance product, providing access to health care for more North Carolinians.

Key Points: 
  • WOONSOCKET, R.I., Aug. 4, 2021 /PRNewswire/ -- Aetna and CVS Health (NYSE: CVS) will enter the individual insurance exchange marketplace in select counties in North Carolina with their first Aetna CVS Health hybrid-branded insurance product, providing access to health care for more North Carolinians.
  • Aetna and CVS Health bring together quality along with convenience and expanded services to meet consumer health needs, simply and affordably.
  • Additionally, the plan provides members with unique and convenient health care offerings at MinuteClinic, HealthHUB and CVS Pharmacy locations across the country.
  • 20% off select CVS Health Brand health and wellness products at any one of the 10,000 CVS Pharmacy stores.

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Medical specialties, Hepatitis, Health sciences, Specialty drugs, Steatohepatitis, Genuity, Non-alcoholic fatty liver disease, Biopharmaceutical

Terns management will also present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 1:00pm ET.

Key Points: 
  • Terns management will also present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 1:00pm ET.
  • A live webcast of the events will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com .
  • A replay of the webcasts will be archived on Terns website for 30 days following the presentations.
  • Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.

MMIT Announces Sixth-Annual Specialty Pharmacy Patient Choice Awards

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Articles, Health, Specialty drugs, Specialty pharmacy, Health care quality, Patient satisfaction, Pharmacy, Net promoter score, Customer satisfaction

Yardley, PA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Managed Markets Insight & Technology (MMIT), the trusted go-to-market partner solely focused on solving the what and why of market accessso that patients dont face delays when trying to access lifesaving drugshas announced the finalists of the sixth-annual Specialty Pharmacy Patient Choice Awardsbased on patient satisfaction survey results from the previous year.

Key Points: 
  • Yardley, PA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Managed Markets Insight & Technology (MMIT), the trusted go-to-market partner solely focused on solving the what and why of market accessso that patients dont face delays when trying to access lifesaving drugshas announced the finalists of the sixth-annual Specialty Pharmacy Patient Choice Awardsbased on patient satisfaction survey results from the previous year.
  • Each year, MMIT recognizes specialty pharmacies that provide best-in-class customer satisfaction and overall patient care within four categories: Payer/PBM, Hospital and Health System, Independent and Retail.
  • The finalists and winners are calculated based on the highest average Net Promoter Score (NPS) from the Zitter Insights Specialty Pharmacy Patient Satisfaction Survey, which provides clients with data they can trust to help them improve patient satisfaction and increase scripts.
  • Were thrilled to once again recognize those who are leading the pack in the specialty pharmacy industry, said MMIT CEO Mike Gallup.

AscellaHealth and Appro-Rx Partner to Provide Specialty Pharmacy Services for Improved Patient Outcomes and Lower Payer Costs

Retrieved on: 
Tuesday, August 3, 2021
Technology, Hospitals, Other Technology, Software, Practice Management, Managed care, Health, Pharmaceutical, Data management, Health sciences, Life sciences, Health care, Pharmacy, Specialty drugs, Clinical pharmacology, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States, Specialty pharmacy, Adherence, Prescription drug

Dea Belazi, president and CEO, AscellaHealth, says, “This exciting partnership will support advances in specialty medication compliance and foster a high level of plan member satisfaction -- while helping payers rein in the staggering costs of specialty drugs.”

Key Points: 
  • AscellaHealth , a global specialty pharmacy and healthcare solutions company, today announces a partnership with Appro-Rx , a national prescription benefit management company, to become its specialty pharmacy services and solutions provider.
  • Specialty drugs are vastly more expensive than their traditional drug counterparts, and this partnership not only enables our clients to realize significant cost savings but also to improve health outcomes for their employees.
  • AscellaHealths innovative specialty pharmacy and infusion services provide cost-saving discounts on prescription medications with timely access to therapies, data-driven reporting and patient support programsall of which help to improve patient adherence and health outcomes, thereby optimizing the patient journey.
  • AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving payers, providers, life sciences and patients, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services.

Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Health, Philanthropy, General Health, Public relations, Investor relations, Pharmaceutical, Communications, Other Philanthropy, Hospitals, Fund Raising, Foundation, Biotechnology, Life sciences, Specialty drugs, Gilead Sciences, Gilead, Articles

The Gilead Foundation, established in 2005, builds on the companys longstanding commitment to supporting underserved communities around the world.

Key Points: 
  • The Gilead Foundation, established in 2005, builds on the companys longstanding commitment to supporting underserved communities around the world.
  • Giving back to charitable organizations in the communities in which we live and work has helped define Gilead as a company, said Keeley Wettan, Senior Vice President, Legal, Gilead Sciences and Gilead Foundation Board Chair.
  • The Gilead Foundation has three core programs: the Creating Possible Fund, charitable donations to local community organizations and the donation matching program for employees.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

ReCode Therapeutics to Participate in Upcoming August Investor Conferences

Retrieved on: 
Tuesday, August 3, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Life sciences, Articles, Biotechnology, Pharmaceutical industry, Pharmacy, Specialty drugs, Ciliopathy, Primary ciliary dyskinesia, Biopharmaceutical, Gene editing, Arcturus Therapeutics

ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will host 1x1 meetings at two upcoming virtual investor conferences in August:

Key Points: 
  • ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will host 1x1 meetings at two upcoming virtual investor conferences in August:
    ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using powerful LNP delivery technology to target organs and tissues beyond the liver.
  • The Companys pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia.
  • The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells.
  • For more information, visit www.recodetx.com and follow us on Twitter @ ReCodeTx and LinkedIn .

Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Monday, August 2, 2021
Life sciences, Pharmaceutical industry, Health sciences, Natural sciences, Specialty drugs, Medication, Biopharmaceutical, Wedbush Securities

HAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe 2021 Wedbush PacGrow Healthcare Conference onTuesday, August 10, 2021 at 2:55 p.m. Eastern Time.

Key Points: 
  • HAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe 2021 Wedbush PacGrow Healthcare Conference onTuesday, August 10, 2021 at 2:55 p.m. Eastern Time.
  • A live webcast of Kiniksas presentation will be accessible through the Investors & Media section of the companys website at www.kiniksa.com .
  • A replay of the webcast will be available on Kiniksas website for 14 days following the conference.
  • Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.

CytomX Therapeutics to Present at Upcoming August Investor Conferences

Retrieved on: 
Monday, August 2, 2021
Life sciences, Biotechnology, Health sciences, Pharmaceutical industry, Pharmacy, Specialty drugs, Biopharmaceutical

In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

Key Points: 
  • In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
  • CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies.
  • We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment.